The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs ...

A year after a major layoff round at its Allergan headquarters in California, AbbVie is making more edits to its workforce with a new round of 85 layoffs.  | The layoffs at AbbVie's Irvine, California ...

AbbVie's 85 layoffs are tied to its Allergan Aesthetics headquarters in California, while Novartis is cutting more staff at its U.S. HQ in New Jersey.

Gilead Sciences and the World Health Organization (WHO) are doubling down on a pact to eliminate deadly parasitic disea | ...

A web of mail-order pharmacies, wholesalers and patient services groups connected to the self-styled largest Pentecostal ...

After the drug’s local license holder called for a brief pause in new patient starts last week, doctors in Japan can once ...

Healthcare agencies remain at the forefront of pharmaceutical marketing, but new technologies and shifting political dynamics ...

Bristol Myers Squibb is the latest large pharma company to be making a major bet on artificial intelligence, announcing a sweeping agreement with Anthropic to deploy its AI tool Claude as the “shared ...

After some six years at the post, Amgen’s finance chief is telegraphing his exit from the California pharma by early next ...

An Ipsen-commissioned survey has identified widespread problems with the transition from pediatric to adult healthcare, ...

Gilead Sciences has broadened its partnership with Korean manufacturer Yuhan, agreeing to a 210 billion Korean won ($140 million) supply deal for active pharmaceutical ingredients (API) for an ...

As Eli Lilly moves to set up a mammoth manufacturing facility in Houston, it’s not the only U.S. pharma juggernaut with an ...